ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines-Reference-Cited by-同舟云学术

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines

Published:2007-05-21 Issue:50 Volume:26 Page:7163-7169
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Ginestier C,Adélaïde J,Gonçalvès A,Repellini L,Sircoulomb F,Letessier A,Finetti P,Geneix J,Charafe-Jauffret E,Bertucci F,Jacquemier J,Viens P,Birnbaum D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/1210528.pdf

Reference39 articles.

1. Adélaïde J, Huang HE, Murati A, Alsop AE, Orsetti B, Mozziconacci MJ et al. (2003). A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. Genes Chromosomes Cancer 37: 333–345.

2. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S et al. (2005). Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24: 4540–4548.

3. Badache A, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A . (2004). Memo mediates ErbB2-driven cell motility. Nat Cell Biol 6: 515–522.

4. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V et al. (2005). Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162–2171.

5. Baselga J, Gianni I, Geyer C, Perez EA, Riva A, Jackisch C . (2004). Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 31: 51–57.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy;Drug Resistance Updates;2024-05

2. Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancer;Current Issues in Molecular Biology;2024-03-21

3. ZNF217 Gene Copy Number as a Marker of Response to Standard Therapy Drugs According to ERα Status in Breast Cancer;Breast Cancer: Targets and Therapy;2024-03

4. HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies;Life;2023-12-29

5. ErbB2_pY_‐1248 as a predictive biomarker for Parkinson's disease based on research with RPPA technology and in vivo verification;CNS Neuroscience & Therapeutics;2023-08-11